Xilio Therapeutics annual operating margin
2024
2025
Xilio Therapeutics's operating margin was −95.92% for fiscal 2025.
View full Xilio Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −95.92% | +859.03 pp |
| 2024 | 2024-12-31 | −954.95% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −18.68% | +159.03 pp |
| Q1 2026 | 2026-03-31 | −111.57% | +361.16 pp |
| Q4 2025 | 2025-12-31 | −86.48% | +565.84 pp |
| Q3 2025 | 2025-09-30 | −10.12% | +613.73 pp |
| Q2 2025 | 2025-06-30 | −177.71% | — |
| Q1 2025 | 2025-03-31 | −472.73% | — |
| Q3 2024 | 2024-09-30 | −652.32% | — |
| Q2 2024 | 2024-06-30 | −623.84% | — |
Across the available reported history, Xilio Therapeutics's operating margin increased from −954.95% to −95.92%, a change of +859.03 percentage points. The latest reported quarter, Q2 2026, shows −18.68%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics filings at SEC.gov ↗